NN2211, a Novo Nordisk GLP-1 derivate, suppresses appetite in wild type but not in GLP-1R-/- mice

被引：0
|
作者：
Bjenning, CA [1 ]
Romer, J [1 ]
Knudsen, LB [1 ]
机构：
[1] Novo Nordisk AS, DK-2820 Gentofte, Denmark
来源：
OBESITY RESEARCH | 2001年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：119S / 119S
页数：1
相关论文
共 50 条
  • [21] The long-acting GLP-1 derivative, NN2211, restores beta cell sensitivity to glucose in subjects with type 2 diabetes
    Chang, A
    Jakobsen, G
    Sturis, J
    An, B
    Smith, M
    Bloem, C
    Galecki, A
    Halter, J
    DIABETES, 2003, 52 : A113 - A113
  • [22] Victoza - Liraglutide - Novo Nordisk - A GLP-1 analog for the treatment of type 2 diabetes
    不详
    FORMULARY, 2010, 45 (03) : 76 - 76
  • [23] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
    Agerso, H
    Jensen, LB
    Elbrond, B
    Rolan, P
    Zdravkovic, M
    DIABETOLOGIA, 2002, 45 (02) : 195 - 202
  • [24] Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes
    Feinglos, MN
    Saad, MF
    Pi-Sunyer, FX
    An, B
    Santiago, O
    DIABETIC MEDICINE, 2005, 22 (08) : 1016 - 1023
  • [25] The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
    H. Agersø
    L. B. Jensen
    B. Elbrønd
    P. Rolan
    M. Zdravkovic
    Diabetologia, 2002, 45 : 195 - 202
  • [26] The long-acting GLP-1 derivative, NN2211, restores beta cell sensitivity to glucose in subjects with Type 2 diabetes.
    Chang, AM
    Jakobsen, G
    Sturis, J
    An, B
    Smith, MJ
    Bloem, CJ
    Halter, JB
    DIABETOLOGIA, 2003, 46 : A285 - A285
  • [27] No impairment of hypoglycemia counterregulation via glucagon with the long-acting GLP-1 derivative, NN2211, in subjects with Type 2-diabetes.
    Nauck, MA
    El-Ouaghlidi, A
    Hompesch, M
    Jacobsen, J
    Elbroend, B
    DIABETOLOGIA, 2003, 46 : A285 - A285
  • [28] The GLP-1 analogue, NN2211, inhibits free fatty acid-induced apoptosis in primary rat β-cells.
    Bregenholt, S
    Moldrup, A
    Blume, N
    Knudsen, LB
    Petersen, JS
    DIABETOLOGIA, 2001, 44 : A19 - A19
  • [29] NN2211, a protracted GLP-1 derivative, ameliorates glycaemia and reduces triglyceride levels in pre-diabetic ZDF rats
    Rolin, B
    Gotfredsen, C
    Sturis, J
    Wilken, M
    Nygaard, H
    Carr, RD
    Knudsen, LB
    DIABETES, 2001, 50 : A312 - A312
  • [30] Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes
    Juhl, CB
    Hollingdal, M
    Sturis, J
    Jakobsen, G
    Agerso, H
    Veldhuis, J
    Porksen, N
    Schmitz, O
    DIABETES, 2002, 51 (02) : 424 - 429
12345